semaglutide patents Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely? On March 20, 2026, the patent protecting Novo Nordisk's expired in India. Within 24 hours, the market transformed. Leading pharmaceutical giants New Delhi, March 19, 2026

Until pediatric trials are completed and reviewed, retatrutide should not be used in anyone under 18

These architectures introduce gating mechanisms that enable more stable and accurate performance when processing complex time series data

Embryonic fibroblasts from Gpx4(+/) mice: A novel model for studying the role of membrane peroxidation in biological processes

The news: Digital health company Noom is rolling out a new preventive health program that offers microdoses of GLP-1 medications alongside at-home biomarker testing

Retatrutide 10mg*10vials Product Details About This Product Retatrutide is a triple GIP/GLP-1/GCG receptor agonist developed for advanced metabolic research applications